BiondVax Pharmaceuticals Ltd. (TASE:BNDX) today notified the Tel Aviv Stock Exchange (TASE) of indications of possible success in a trial of the effectiveness of its universal influenza vaccine on H1N1/A flu (swine flu).
Trading in the biotech company's share was suspended, after it rose 18%, apparently on rumors of the notification.
BiondVax said that antibodies specific to swine flu were found in blood samples from lab rats injected with the universal flu vaccine. The antibodies identified the H1N1/A strain of flu, compared with the control group of rats in which no specific antibodies were created.
BiondVax cautioned that these preliminary results are insufficient to verify whether the universal flu vaccine can protect people against swine flu. It added that the results were based on a small sample of a dead H1N1/A strain of flu taken from people.
The trial was conducted on five rats, with additional rats used for control.
Published by Globes [online], Israel business news - www.globes-online.com - on August 25, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009